Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
p53
tumor-suppressor protein prevents cancer development through various mechanisms, including the induction of cell-cycle arrest, apoptosis, and the maintenance of genome stability. We have identified a
p53
-inducible gene named
TIGAR
(
TP53-induced glycolysis and apoptosis regulator
).
TIGAR
expression lowered fructose-2,6-bisphosphate levels in cells, resulting in an inhibition of glycolysis and an overall decrease in intracellular reactive oxygen species (ROS) levels. These functions of
TIGAR
correlated with an ability to protect cells from ROS-associated apoptosis, and consequently, knockdown of endogenous
TIGAR
expression sensitized cells to
p53
-induced death. Expression of
TIGAR
may therefore modulate the apoptotic response to
p53
, allowing survival in the face of mild or transient stress signals that may be reversed or repaired. The decrease of intracellular ROS levels in response to
TIGAR
may also play a role in the ability of
p53
to protect from the accumulation of genomic damage.
...
PMID:TIGAR, a p53-inducible regulator of glycolysis and apoptosis. 1683 73
The function of
p53
as a tumor suppressor remains undisputed.
p53
has a central role in cellular stress responses as well as affecting cancer development and progression. The word "central", however, is becoming increasingly more of an understatement as the list of
p53
-regulated pathways and processes is ever expanding. Although much focus continues to center on
p53
-mediated signaling cascades that control cell growth arrest and/or apoptosis, recent work has begun to define a role for
p53
in the regulation of metabolic pathways typically thought of as essential for maintaining life. With the first potential link between
p53
and glycolysis reported nearly ten years ago, the topic has gained a renewed interest. Recent studies now demonstrate the ability of
p53
to regulate the expression of several novel genes including PGM (phosphoglycerate mutase),
TIGAR
(
TP53-induced glycolysis and apoptosis regulator
) and, SCO2 (synthesis of cytochrome c oxidase 2), each intimately linked to the processes of glycolysis and oxidative phosphorylation. With this discovery, yet another novel means by which
p53
carries out its tumor suppressor function is brought into light.
...
PMID:The regulation of energy generating metabolic pathways by p53. 1720 63
The histidine phosphatase superfamily is a large functionally diverse group of proteins. They share a conserved catalytic core centred on a histidine which becomes phosphorylated during the course of the reaction. Although the superfamily is overwhelmingly composed of phosphatases, the earliest known and arguably best-studied member is dPGM (cofactor-dependent phosphoglycerate mutase). The superfamily contains two branches sharing very limited sequence similarity: the first containing dPGM, fructose-2,6-bisphosphatase, PhoE, SixA,
TIGAR
[
TP53
(tumour protein 53)-induced glycolysis and apoptosis regulator], Sts-1 and many other activities, and the second, smaller, branch composed mainly of acid phosphatases and phytases. Human representatives of both branches are of considerable medical interest, and various parasites contain superfamily members whose inhibition might have therapeutic value. Additionally, several phosphatases, notably the phytases, have current or potential applications in agriculture. The present review aims to draw together what is known about structure and function in the superfamily. With the benefit of an expanding set of histidine phosphatase superfamily structures, a clearer picture of the conserved elements is obtained, along with, conversely, a view of the sometimes surprising variation in substrate-binding and proton donor residues across the superfamily. This analysis should contribute to correcting a history of over- and mis-annotation in the superfamily, but also suggests that structural knowledge, from models or experimental structures, in conjunction with experimental assays, will prove vital for the future description of function in the superfamily.
...
PMID:The histidine phosphatase superfamily: structure and function. 1809 46
Activation of the
p53 tumor suppressor
by cellular stress leads to variable responses ranging from growth inhibition to apoptosis.
TIGAR
is a novel
p53
-inducible gene that inhibits glycolysis by reducing cellular levels of fructose-2,6-bisphosphate, an activator of glycolysis and inhibitor of gluconeogenesis. Here we describe structural and biochemical studies of
TIGAR
from Danio rerio. The overall structure forms a histidine phosphatase fold with a phosphate molecule coordinated to the catalytic histidine residue and a second phosphate molecule in a position not observed in other phosphatases. The recombinant human and zebra fish enzymes hydrolyze fructose-2,6-bisphosphate as well as fructose-1,6-bisphosphate but not fructose 6-phosphate in vitro. The
TIGAR
active site is open and positively charged, consistent with its enzymatic function as bisphosphatase. The closest related structures are the bacterial broad specificity phosphatase PhoE and the fructose-2,6-bisphosphatase domain of the bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. The structural comparison shows that
TIGAR
combines an accessible active site as observed in PhoE with a charged substrate-binding pocket as seen in the fructose-2,6-bisphosphatase domain of the bifunctional enzyme.
...
PMID:Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator). 1901 59
The
p53
-inducible
TIGAR
protein functions as a fructose-2,6-bisphosphatase, promoting the pentose phosphate pathway and helping to lower intracellular reactive oxygen species (ROS). ROS functions in the regulation of many cellular responses, including autophagy--a response to stress conditions such as nutrient starvation and metabolic stress. In this study, we show that
TIGAR
can modulate ROS in response to nutrient starvation or metabolic stress, and functions to inhibit autophagy. The ability of
TIGAR
to limit autophagy correlates strongly with the suppression of ROS, with no clear effects on the mTOR pathway, and is
p53
independent. The induction of autophagy in response to loss of
TIGAR
can function to moderate apoptotic response by restraining ROS levels. These results reveal a complex interplay in the regulation of ROS, autophagy and apoptosis in response to
TIGAR
expression, and shows that proteins similar to
TIGAR
that regulate glycolysis can have a profound effect on the autophagic response through ROS regulation.
...
PMID:Modulation of intracellular ROS levels by TIGAR controls autophagy. 1971 38
In 1930, Otto Warburg observed that cancer cells produce an increased amount of their energy through aerobic glycolysis and subsequently, this was called the Warburg effect. During aging, the capacity for mitochondrial respiration clearly declines and aerobic glycolysis appears to compensate for the deficiency in oxidative metabolism. This shift in energy production, both in aging and cancer, could protect from the toxic effects of oxygen free radicals whereas increased glycolysis can have adverse effects. It was recently demonstrated that the glycolysis-linked protein O-glycosylation can potentiate the catalytic activity of IKK beta and subsequently trigger NF-kappaB signaling. It seems that tumor suppressor oncogene
p53
has an important role in the regulation of protein O-glycosylation since
p53
is a potent inhibitor of glycolysis, for example, via
TIGAR
protein expression. Aging is known to repress the function of
p53
and this could enhance glycolysis and NF-kappaB signaling. We will discuss the role of
p53
in the regulation of glycolysis-dependent activation of NF-kappaB signaling in both cancer and aging process.
...
PMID:Glycolysis links p53 function with NF-kappaB signaling: impact on cancer and aging process. 2030 Dec 5
Bioenergetic homeostasis is altered in heart failure and may play an important role in pathogenesis.
p53
has been implicated in heart failure, and although its role in regulating tumorigenesis is well characterized, its activities on cellular metabolism are just beginning to be understood. We investigated the role of
p53
and its transcriptional target gene
TP53-induced glycolysis and apoptosis regulator
(
TIGAR
) in myocardial energy metabolism under conditions simulating ischemia that can lead to heart failure. Expression of
p53
and
TIGAR
was markedly upregulated after myocardial infarction, and apoptotic myocytes were decreased by 42% in
p53
-deficient mouse hearts compared with those in wild-type mice. To examine the effect of
p53
on energy metabolism, cardiac myocytes were exposed to hypoxia. Hypoxia induced
p53
and
TIGAR
expression in a
p53
-dependent manner. Knockdown of
p53
or
TIGAR
increased glycolysis with elevated fructose-2,6-bisphosphate levels and reduced myocyte apoptosis. Hypoxic stress decreased phosphocreatine content and the mitochondrial membrane potential of myocytes without changes in ATP content, the effects of which were prevented by the knockdown of
TIGAR
. Inhibition of glycolysis by 2-deoxyglucose blocked these bioenergetic effects and
TIGAR
siRNA-mediated prevention of apoptosis, and, in contrast, overexpression of
TIGAR
reduced glucose utilization and increased apoptosis. Our data demonstrate that
p53
and
TIGAR
inhibit glycolysis in hypoxic myocytes and that inhibition of glycolysis is closely involved in apoptosis, suggesting that
p53
and
TIGAR
are significant mediators of cellular energy homeostasis and cell death under ischemic stress.
...
PMID:p53 and TIGAR regulate cardiac myocyte energy homeostasis under hypoxic stress. 2093 45
The preferential use of aerobic glycolysis for energy production by cancer cells, a phenomenon known as the 'Warburg effect', is well recognized and is being considered for therapeutic applications. However, whether inhibition of glycolysis will be effective in all types of cancer is unclear. The current study shows that a glycolytic inhibitor, 2-deoxy-D-glucose (2DG), exhibits the cytotoxic effect on non-small cell lung cancer in a
p53
-dependent manner. 2DG significantly inhibits ATP production in
p53
-deficient lung cancer cells (H358) but not in
p53
-wt cells (A549). In contrast to
p53
-wt cells,
p53
-defective cells are unable to compensate for their need of energy via oxidative phosphorylation (OXPHOS) when glycolysis is inhibited. In the presence of
p53
, increased ROS from OXPHOS increases the expression of p53 target genes known to modulate metabolism, including synthesis of cytochrome c oxidase 2 (SCO2) and
TP53-induced glycolysis and apoptosis regulator
(
TIGAR
). Importantly, 2DG selectively induces the expression of the antioxidant enzymes manganese superoxide dismutase (MnSOD) and glutathione peroxidase 1 (GPx1) in a
p53
-dependent manner. The results demonstrate that the killing of cancer cells by the inhibitor of glycolysis is more efficient in cancer cells without functional
p53
and that
p53
protects against metabolic stress by up-regulation of oxidative phosphorylation and modulation of antioxidants.
...
PMID:p53 Protects lung cancer cells against metabolic stress. 2104 27
Cancer cells show a higher rate of anaerobic respiration than normal cells. The exact mechanisms for this higher glycolysis rate in cancer cells remain to be elucidated. The results of recent studies have indicated that
p53
, the most commonly mutated tumor suppressor gene, may have important functions in the regulation of energy-generating metabolic pathways that switch from oxidative phosphorylation to glycolysis via the synthesis of cytochrome c oxidase 2 (SCO2),
p53
-transactivated
TP53
-induced glycolysis (
TIGAR
), and apoptosis regulator. We evaluated the expression of
p53
, SCO2,
TIGAR
, and COX in 113 cases of invasive breast cancer using immunohistochemistry. A high expression of
p53
, SCO2,
TIGAR
, and COX was noted in 27.5% (31 cases), 84.1% (95 cases), 74.3% (84 cases), and 73.4% (83 cases) of the breast tumors, respectively. A high
p53
expression was significantly associated with low expression levels of SCO2 (P = .008), COX (P < .0001), and
TIGAR
(P = .007). On the survival analysis, the low SCO2-expressing breast cancer patients showed a significantly poorer prognosis than that of the high SCO2-expressing breast cancer patients (P = .0078). These results suggest that
p53
can modulate the metabolic pathways via the proteins SCO2 and
TIGAR
in human breast cancer.
...
PMID:Regulatory role of p53 in cancer metabolism via SCO2 and TIGAR in human breast cancer. 2182 Jan 50
D-Galactose (D-gal) can induce oxidative stress in non-cancer cells and result in cell damage by disturbing glucose metabolism. However, the effect of D-gal on cancer cells is yet to be explored. In this study, we investigated the toxicity of D-gal to malignant cells specifically neuroblastoma cells. As the results, high concentrations of D-gal had significant toxicity to cancer cells, whereas the same concentrations of glucose had no; the viability loss via D-gal treatment was prominent to malignant cells (Neuro2a, SH-SY5Y, PC-3, and HepG2) comparing to non-malignant cells (NIH3T3 and LO(2)). Differing from the apoptosis induced by H(2) O(2), D-gal damaged cells showed the characters of necrotic cell death, such as trypan blue-tangible and early phase LDH leakage. Further experiments displayed that the toxic effect of D-gal can be alleviated by necroptosis inhibitor Necrostatin (Nec-1) and autophagy inhibitor 3-methyladenine (3-MA) but not by caspase inhibitor z-VAD-fmk. D-Gal treatment can transcriptionally up-regulate the genes relevant to necroptosis (Bmf, Bnip3) and autophagy (Atg5,
TIGAR
) but not the genes related to apoptosis (Caspase3, Bax, and
p53
). D-Gal did not activate Caspase-3, but prompted puncta-like GFP-LC3 distribution, an indicator for activated autophagy. The involvement of aldose reductase (AR)-mediated polyol pathway was proved because the inhibitor of AR can attenuate the toxicity of D-gal and D-gal treatment elevates the expression of AR. This study demonstrates for the first time that D-gal can induce non-apoptotic but necroptotic cell death in neuroblastoma cells and provides a new clue for developing the strategy against apoptosis-resistant cancers.
...
PMID:D-galactose induces necroptotic cell death in neuroblastoma cell lines. 2182 10
1
2
3
4
5
6
7
Next >>